TY - JOUR
T1 - Chronic myeloid leukemia 2011
T2 - Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop
AU - Mughal, Tariq I.
AU - Radich, Jerald P.
AU - van Etten, Richard A.
AU - Quintás-Cardama, Alfonso
AU - Skorski, Tomasz
AU - Ravandi, Farhad
AU - Deangelo, Daniel J.
AU - Gambacorti-Passerini, Carlo
AU - Martinelli, Giovanni
AU - Tefferi, Ayalew
PY - 2011/9
Y1 - 2011/9
N2 - This report is based on the presentations and discussions at the 5
th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms (MPN) workshop, which took place immediately following the 52
nd American Society of Hematology (ASH) meeting in Orlando, Florida on December 7
th-8
th, 2011. Relevant data which was presented at the ASH meeting as well as all other recent publications were presented and discussed at the workshop. This report covers front-line therapies of BCR-ABL1-positive leukemias, in addition to addressing some topical biological, pre-clinical and clinical issues, such as new insights into genomic instability and resistance to tyrosine kinase inhibitors (TKIs), risk stratification and optimizing molecular monitoring. A report pertaining to the new therapies and other pertinent preclinical and clinical issues in the BCR-ABL1 negative MPNs is published separately.
AB - This report is based on the presentations and discussions at the 5
th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms (MPN) workshop, which took place immediately following the 52
nd American Society of Hematology (ASH) meeting in Orlando, Florida on December 7
th-8
th, 2011. Relevant data which was presented at the ASH meeting as well as all other recent publications were presented and discussed at the workshop. This report covers front-line therapies of BCR-ABL1-positive leukemias, in addition to addressing some topical biological, pre-clinical and clinical issues, such as new insights into genomic instability and resistance to tyrosine kinase inhibitors (TKIs), risk stratification and optimizing molecular monitoring. A report pertaining to the new therapies and other pertinent preclinical and clinical issues in the BCR-ABL1 negative MPNs is published separately.
KW - Animals
KW - Antineoplastic Agents/therapeutic use
KW - Drug Monitoring
KW - Drug Resistance, Neoplasm
KW - Genomic Instability
KW - Humans
KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
KW - Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=80051739930&partnerID=8YFLogxK
U2 - 10.1002/ajh.22097
DO - 10.1002/ajh.22097
M3 - Article
C2 - 21850662
AN - SCOPUS:80051739930
SN - 0361-8609
VL - 86
SP - 811
EP - 819
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 9
ER -